Potential Patient-Reported Toxicities With Disulfiram Treatment in Late Disseminated Lyme Disease.
benefit
disulfiram
lyme disease
patient-reported adverse drug reactions
risk
Journal
Frontiers in medicine
ISSN: 2296-858X
Titre abrégé: Front Med (Lausanne)
Pays: Switzerland
ID NLM: 101648047
Informations de publication
Date de publication:
2020
2020
Historique:
received:
10
12
2019
accepted:
27
03
2020
entrez:
7
5
2020
pubmed:
7
5
2020
medline:
7
5
2020
Statut:
epublish
Résumé
Recently, disulfiram has been proposed as a promising treatment for people suffering from persistent symptoms of Lyme Disease. Disulfiram has several distinct molecular targets. The most well-known is alcohol dehydrogenase, a key enzyme for detoxifying the organism after alcohol ingestion. Other targets and modes of action of disulfiram, that may present problematic side effects, are less commonly mentioned. The
Identifiants
pubmed: 32373619
doi: 10.3389/fmed.2020.00133
pmc: PMC7184924
doi:
Types de publication
Journal Article
Langues
eng
Pagination
133Informations de copyright
Copyright © 2020 Trautmann, Gascan and Ghozzi.
Références
J Fr Ophtalmol. 2006 Oct;29(8):924-8
pubmed: 17075509
Clin Neuropharmacol. 2016 Sep-Oct;39(5):272-5
pubmed: 27466724
Ir J Psychol Med. 2007 Sep;24(3):115-116
pubmed: 30290491
Eur J Cancer Prev. 2010 Nov;19(6):431-65
pubmed: 20679896
Crit Rev Clin Lab Sci. 2003 Apr;40(2):183-208
pubmed: 12755455
Biochem Pharmacol. 2000 Oct 1;60(7):947-53
pubmed: 10974203
J Clin Oncol. 2015 Mar 10;33(8):910-5
pubmed: 25624439
Eur J Cancer. 2014 Mar;50(5):953-62
pubmed: 24424105
Antimicrob Agents Chemother. 2017 Aug 24;61(9):
pubmed: 28674046
Antimicrob Agents Chemother. 2014 Jul;58(7):3727-36
pubmed: 24752262
Nihon Ishinkin Gakkai Zasshi. 2007;48(3):109-13
pubmed: 17667894
Oxid Med Cell Longev. 2019 Jan 9;2019:2593742
pubmed: 30728884
Ann N Y Acad Sci. 2001 Mar;933:235-53
pubmed: 12000024
Int J Antimicrob Agents. 2019 Jun;53(6):709-715
pubmed: 30954635
Int J Cancer. 2006 Mar 15;118(6):1577-80
pubmed: 16206267
J Neuropsychiatry Clin Neurosci. 2013 Summer;25(3):176-86
pubmed: 24026711
Eur J Neurosci. 2008 Sep;28(6):1180-90
pubmed: 18783367
CNS Neurol Disord Drug Targets. 2010 Mar;9(1):5-12
pubmed: 20201810
Nature. 2017 Dec 14;552(7684):194-199
pubmed: 29211715
Alcohol Alcohol. 1989;24(5):429-37
pubmed: 2554935
Mol Pharmacol. 2004 Mar;65(3):675-84
pubmed: 14978246
Front Med (Lausanne). 2017 Dec 14;4:224
pubmed: 29312942
Br J Cancer. 2011 May 10;104(10):1564-74
pubmed: 21487404
Antibiotics (Basel). 2019 May 30;8(2):
pubmed: 31151194
Antimicrob Agents Chemother. 2015 Aug;59(8):4835-44
pubmed: 26033731
Carcinogenesis. 2014 Mar;35(3):692-702
pubmed: 24193513
Drug Des Devel Ther. 2016 Apr 01;10:1307-22
pubmed: 27103785
Am J Cancer Res. 2019 Jun 01;9(6):1266-1281
pubmed: 31285958
Proc Natl Acad Sci U S A. 1979 Oct;76(10):5303-7
pubmed: 388434
BMJ Open Gastroenterol. 2019 Aug 5;6(1):e000325
pubmed: 31423320
Cell Biol Toxicol. 2012 Feb;28(1):1-9
pubmed: 21866320
Oral Dis. 2015 Sep;21(6):748-54
pubmed: 25809116
Am J Epidemiol. 2001 Mar 15;153(6):604-9
pubmed: 11257069
Clin Psychopharmacol Neurosci. 2017 Feb 28;15(1):68-69
pubmed: 28138114
Antimicrob Agents Chemother. 2012 Aug;56(8):4140-5
pubmed: 22615274